AGLE
Price:
$12.01
Market Cap:
$48.63M
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly kno...[Read more]
Industry
Biotechnology
IPO Date
2016-04-07
Stock Exchange
NASDAQ
Ticker
AGLE
According to Aeglea BioTherapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 197.28%. This represents a change of 2.63% compared to the average of 7.22% of the last 4 quarters.
The mean historical ROE of Aeglea BioTherapeutics, Inc. over the last ten years is -116.68%. The current 197.28% ROE has changed -269.08% with respect to the historical average. Over the past ten years (40 quarters), AGLE's ROE was at its highest in in the June 2023 quarter at 104.68%. The ROE was at its lowest in in the December 2014 quarter at -169.93%.
Average
-116.68%
Median
-61.60%
Minimum
-552.72%
Maximum
0%
Discovering the peaks and valleys of Aeglea BioTherapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 112.55%
Maximum Annual ROE = 0%
Minimum Annual Increase = -Infinity%
Minimum Annual ROE = -552.72%
Year | ROE | Change |
---|---|---|
2022 | -166.61% | 112.55% |
2021 | -78.39% | 36.51% |
2020 | -57.43% | -54.42% |
2019 | -125.98% | 91.55% |
2018 | -65.77% | 21.56% |
2017 | -54.11% | 57.02% |
2016 | -34.46% | 10.15% |
2015 | -31.28% | -94.34% |
2014 | -552.72% | -Infinity% |
The current ROE of Aeglea BioTherapeutics, Inc. (AGLE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-100.81%
5-year avg
-98.84%
10-year avg
-116.68%
Aeglea BioTherapeutics, Inc.’s ROE is greater than Edgewise Therapeutics, Inc. (-28.01%), greater than Ikena Oncology, Inc. (-42.81%), greater than Design Therapeutics, Inc. (-18.48%), greater than Xilio Therapeutics, Inc. (-176.51%), greater than Eliem Therapeutics, Inc. (-47.03%), less than eFFECTOR Therapeutics, Inc. (2.18%), greater than Landos Biopharma, Inc. (-73.00%), greater than Apexigen, Inc. (-606.56%), greater than Navidea Biopharmaceuticals, Inc. (-173.56%), greater than Angion Biomedica Corp. (-113.71%), greater than SAB Biotherapeutics, Inc. (-94.04%), greater than Senti Biosciences, Inc. (-91.09%), less than Cingulate Inc. (11.47%), less than Bellicum Pharmaceuticals, Inc. (153.34%), greater than Hillstream BioPharma, Inc. (-47249.59%), greater than Neoleukin Therapeutics, Inc. (-47.64%), greater than CytomX Therapeutics, Inc. (-27.44%), greater than Assembly Biosciences, Inc. (-121.55%), greater than Instil Bio, Inc. (-55.57%), greater than Nuvation Bio Inc. (-98.79%), greater than Applied Molecular Transport Inc. (-218.56%), less than Catalyst Biosciences, Inc. (1.20%), greater than Aileron Therapeutics, Inc. (-47.94%), greater than Bio-Path Holdings, Inc. (-2842.40%), greater than Benitec Biopharma Inc. (-90.14%),
Company | ROE | Market cap |
---|---|---|
-28.01% | $3.19B | |
-42.81% | $83.00M | |
-18.48% | $294.43M | |
-176.51% | $58.02M | |
-47.03% | $342.68M | |
2.18% | $1.88K | |
-73.00% | $71.68M | |
-606.56% | $9.57M | |
-173.56% | $100.08K | |
-113.71% | $30.11M | |
-94.04% | $43.70M | |
-91.09% | $9.98M | |
11.47% | $11.72M | |
153.34% | $778.33K | |
-47249.59% | $4.17M | |
-47.64% | $8.20M | |
-27.44% | $82.02M | |
-121.55% | $107.18M | |
-55.57% | $187.18M | |
-98.79% | $767.69M | |
-218.56% | $11.01M | |
1.20% | $19.42M | |
-47.94% | $86.66M | |
-2842.40% | $3.64M | |
-90.14% | $216.38M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aeglea BioTherapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aeglea BioTherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Aeglea BioTherapeutics, Inc.'s ROE?
How is the ROE calculated for Aeglea BioTherapeutics, Inc. (AGLE)?
What is the highest ROE for Aeglea BioTherapeutics, Inc. (AGLE)?
What is the 3-year average ROE for Aeglea BioTherapeutics, Inc. (AGLE)?
What is the 5-year average ROE for Aeglea BioTherapeutics, Inc. (AGLE)?
How does the current ROE for Aeglea BioTherapeutics, Inc. (AGLE) compare to its historical average?